Telemonitoring of 24-Hour Blood Pressure in Local Pharmacies and Blood Pressure Control in the Community: The Templar Project

American Journal of Hypertension

Volumn 32, Issue 7, 2019, Pages 629-639

  Omboni, Stefano ^a,b   Mancinelli, Antonio ^a   Rizzi, Franco ^a   Parati, Gianfranco ^c,d  

^a ITALIAN INSTITUTE OF TELEMEDICINE   (Italy)

^b I M SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY   (Russian Federation)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

ambulatory blood pressure monitoring; blood pressure; blood pressure telemonitoring; hypertension; pharmacy; telehealth; telemedicine

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; COMMUNITY; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MASKED HYPERTENSION; MULTICENTER STUDY; NIGHT; OBSERVATIONAL STUDY; PHARMACY (SHOP); PRIORITY JOURNAL; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; TELEHEALTH; TELEMONITORING; WHITE COAT HYPERTENSION; ADOLESCENT; BLOOD PRESSURE; CLINICAL TRIAL; DRUG EFFECT; HYPERTENSION; ITALY; MIDDLE AGED; PATHOPHYSIOLOGY; PREDICTIVE VALUE; TELEMEDICINE; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; COMMUNITY PHARMACY SERVICES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERTENSION; ITALY; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; TELEMEDICINE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85067908292     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hpz049     Document Type: Article

References (40)

1. Di Palo KE, Kish T. Te role of the pharmacist in hypertension manage-ment. Curr Opin Cardiol 2018; 33:382-387.
2. Omboni S, Caserini M. Efectiveness of pharmacist's intervention in the management of cardiovascular diseases. Open Heart 2018; 5:e000687.
3. Kennelty KA, Polgreen LA, Carter BL. Team-based care with pharmacists to improve blood pressure: a review of recent literature. Curr Hypertens Rep 2018; 20:1.
4. Omboni S, Coronetti C, Tenti M. Physician-pharmacist collaborative practice and telehealth may transform hypertension management. J Human Hypertens. 2019;33:177-187.
5. Parati G, Stergiou G, O'Brien E, Asmar R, Beilin L, Bilo G, Clement D, de la Sierra A, de Leeuw P, Dolan E, Fagard R, Graves J, Head GA, Imai Y, Kario K, Lurbe E, Mallion JM, Mancia G, Mengden T, Myers M, Ogedegbe G, Ohkubo T, Omboni S, Palatini P, Redon J, Ruilope LM, Shennan A, Staessen JA, vanMontfrans G, Verdecchia P, Waeber B, Wang J, Zanchetti A, Zhang Y; European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens 2014; 32:1359-1366.
6. Parati G, Omboni S, Palatini P, Rizzoni D, Bilo G, Valentini M, Rosei EA, Mancia G. Italian society of hypertension guidelines for conventional and automated blood pressure measurement in the ofce, at home and over 24 hours. High Blood Press Cardiovasc Prev 2008; 15:283-310.
7. Ragazzo F, Saladini F, Palatini P. Validation of the Microlife WatchBP O3 device for clinic, home, and ambulatory blood pressure measurement, according to the International Protocol. Blood Press Monit 2010; 15:59-62.
8. Stergiou GS, Tzamouranis D, Nasothimiou EG, Karpettas N, Protogerou A. Are there really diferences between home and daytime ambulatory blood pressure? Comparison using a novel dual-mode ambulatory and home monitor. J Hum Hypertens 2010; 24:207-212.
9. Omboni S, Carabelli G, Ghirardi E, Carugo S. Awareness, treatment, and control of major cardiovascular risk factors in a small-scale Italian community: results of a screening campaign. Vasc Health Risk Manag 2013; 9:177-185.
10. Tocci G, Nati G, Cricelli C, Parretti D, Lapi F, Ferrucci A, Borghi C, Volpe M. Prevalence and control of hypertension in diferent macro-areas in Italy: analysis of a large database by the general practice. High Blood Press Cardiovasc Prev 2016; 23:387-393.
11. Bombelli M, Facchetti R, Mancia G, Grassi G. Big data and blood pressure control: insights from the PAMELA and BP-CARE Study Cohorts. Curr Hypertens Rep 2018; 20:82.
12. Banegas JR, Segura J, Sobrino J, Rodríguez-Artalejo F, de la Sierra A, de la Cruz JJ, Gorostidi M, Sarría A, Ruilope LM; Spanish Society of Hypertension Ambulatory Blood Pressure Monitoring Registry Investigators. Efectiveness of blood pressure control outside the medical setting. Hypertension 2007; 49:62-68.
13. James K, Dolan E, O'Brien E. Making ambulatory blood pressure monitoring accessible in pharmacies. Blood Press Monit 2014; 19:134-139.
14. Omboni S, Aristizabal D, De la Sierra A, Dolan E, Head G, Kahan T, Kantola I, Kario K, Kawecka-Jaszcz K, Malan L, Narkiewicz K, Octavio JA, Ohkubo T, Palatini P, Siègelovà J, Silva E, Stergiou G, Zhang Y, Mancia G, Parati G; ARTEMIS (international Ambulatory blood pressure Registry: TEleMonitoring of hypertension and cardiovascular rISk project) Investigators. Hypertension types defned by clinic and ambulatory blood pressure in 14 143 patients referred to hypertension clinics worldwide. Data from the ARTEMIS study. J Hypertens 2016; 34:2187-2198.
15. Melgarejo JD, Maestre GE, Tijs L, Asayama K, Boggia J, Casiglia E, Hansen T W, Imai Y, Jacobs L, Jeppesen J, Kawecka-Jaszcz K, Kuznetsova T, Li Y, Malyutina S, Nikitin Y, Ohkubo T, Stolarz-Skrzypek K, Wang JG, Staessen JA; International Database on Ambulatory Blood Pressure in Relation to Cardiovascular Outcomes (IDACO) Investigators. Prevalence, treatment, and control rates of conventional and ambulatory hypertension across 10 populations in 3 continents. Hypertension 2017; 70:50-58.
16. Anstey DE, Pugliese D, Abdalla M, Bello NA, Givens R, Shimbo D. An update on masked hypertension. Curr Hypertens Rep 2017; 19:94.
17. de la Sierra A, Vinyoles E, Banegas JR, Segura J, Gorostidi M, de la Cruz JJ, Ruilope LM. Prevalence and clinical characteristics of white-coat hypertension based on diferent defnition criteria in untreated and treated patients. J Hypertens. 2017;35:2388-2394.
18. Banegas JR, Ruilope LM, de la Sierra A, Vinyoles E, Gorostidi M, de la Cruz JJ, Ruiz-Hurtado G, Segura J, Rodríguez-Artalejo F, Williams B. Relationship between clinic and ambulatory blood-pressure measurements and mortality. N Engl J Med 2018; 378:1509-1520.
19. Cuspidi C, Tadic M, Mancia G, Grassi G. White-coat hypertension: the neglected subgroup in hypertension. Korean Circ J 2018; 48:552-564.
20. Asayama K, Tijs L, Li Y, Gu YM, Hara A, Liu YP, Zhang Z, Wei FF, Lujambio I, Mena LJ, Boggia J, Hansen T W, Björklund-Bodegård K, Nomura K, Ohkubo T, Jeppesen J, Torp-Pedersen C, Dolan E, Stolarz-Skrzypek K, Malyutina S, Casiglia E, Nikitin Y, Lind L, Luzardo L, Kawecka-Jaszcz K, Sandoya E, Filipovský J, Maestre GE, Wang J, Imai Y, Franklin SS, O'Brien E, Staessen JA; International Database on Ambulatory Blood Pressure in Relation to Cardiovascular Outcomes (IDACO) Investigators. Setting thresholds to varying blood pressure monitoring intervals difer-entially afects risk estimates associated with white-coat and masked hypertension in the population. Hypertension 2014; 64:935-942.
21. Anstey DE, Colantonio LD, Yano Y, Booth Iii JN, Muntner P. Te importance of using 24-hour and nighttime blood pressure for the identi-fcation of white coat hypertension: data from the Jackson Heart Study. J Clin Hypertens (Greenwich). 2018;20:1176-1182.
22. Manios ED, Koroboki EA, Tsivgoulis GK, Spengos KM, Spiliopoulou IK, Brodie FG, Vemmos KN, Zakopoulos NA. Factors infuencing white-coat efect. Am J Hypertens;21:153-158.
23. Vinyoles E, Felip A, Pujol E, de la Sierra A, Durà R, del Rey RH, Sobrino J, Gorostidi M, de la Figuera M, Segura J, Banegas JR, Ruilope LM; Spanish Society of Hypertension ABPM Registry. Clinical characteristics of isolated clinic hypertension. J Hypertens 2008; 26:438-445.
24. Sheppard J P, Fletcher B, Gill P, Martin U, Roberts N, McManus RJ. Predictors of the home-clinic blood pressure diference: a systematic review and meta-analysis. Am J Hypertens 2016; 29:614-625.
25. Verberk WJ, Tien T, de Leeuw P W. Masked hypertension, a review of the literature. Blood Press Monit 2007; 12:267-273.
26. Banegas JR, Ruilope LM, de la Sierra A, de la Cruz JJ, Gorostidi M, Segura J, Martell N, García-Puig J, Deanfeld J, Williams B. High prevalence of masked uncontrolled hypertension in people with treated hypertension. Eur Heart J 2014; 35:3304-3312.
27. Stergiou GS, Asayama K, Tijs L, Kollias A, Niiranen TJ, Hozawa A, Boggia J, Johansson JK, Ohkubo T, Tsuji I, Jula AM, Imai Y, Staessen JA; International Database on HOme blood pressure in relation to Cardiovascular Outcome (IDHOCO) Investigators. Prognosis of white-coat and masked hypertension: International Database of HOme blood pressure in relation to Cardiovascular Outcome. Hypertension 2014; 63:675-682.
28. Tientcheu D, Ayers C, Das SR, McGuire DK, de Lemos JA, Khera A, Kaplan N, Victor R, Vongpatanasin W. Target organ complications and cardiovascular events associated with masked hypertension and white-coat hypertension: analysis from the Dallas Heart Study. J Am Coll Cardiol 2015; 66:2159-2169.
29. Mallion JM, Clerson P, Bobrie G, Genes N, Vaisse B, Chatellier G. Predictive factors for masked hypertension within a population of controlled hypertensives. J Hypertens 2006; 24:2365-2370.
30. Dolan E, James K. Current approach to masked hypertension: from diagnosis to clinical management. Clin Exp Pharmacol Physiol 2017; 44:1272-1278.
31. Longo D, Dorigatti F, Palatini P. Masked hypertension in adults. Blood Press Monit 2005; 10:307-310.
32. Pierdomenico SD, Pierdomenico AM, Coccina F, Porreca E. Prognosis of masked and white coat uncontrolled hypertension detected by ambulatory blood pressure monitoring in elderly treated hypertensive patients. Am J Hypertens 2017; 30:1106-1111.
33. Trudel X, Brisson C, Gilbert-Ouimet M, Duchaine CS, Dalens V, Talbot D, Milot A. Masked hypertension incidence and risk factors in a prospective cohort study. Eur J Prev Cardiol. 2019;26:231-237.
34. Spannella F, Filipponi A, Giulietti F, Balietti P, Bernardi B, Rosettani G, Sarzani R. Prognostic role of masked and white-coat hypertension: 10-Year mortality in treated elderly hypertensives. J Hum Hypertens. 2018 in press. doi: 10.1038/s41371-018-0140-4
35. Fagard RH, Cornelissen VA. Incidence of cardiovascular events in white-coat, masked and sustained hypertension versus true normotension: a meta-analysis. J Hypertens 2007; 25:2193-2198.
36. Palla M, Saber H, Konda S, Briasoulis A. Masked hypertension and car-diovascular outcomes: an updated systematic review and meta-analysis. Integr Blood Press Control 2018; 11:11-24.
37. Istituto Superiore di Sanità. Il Progetto Cuore. http://www.cuore.iss.it/fattori/CuoreData.asp Accessed 7 February 2019.
38. ISTAT (Istituto Nazionale di Statistica). Annuario Statistico Italiano 2017. https://www4.istat.it/it/archivio/207188 Accessed 7 February 2019.
39. Omboni S, Sala E. Te pharmacist and the management of arterial hy-pertension: the role of blood pressure monitoring and telemonitoring. Expert Rev Cardiovasc Ter 2015; 13:209-221.
40. Omboni S, Tenti M. Telepharmacy for the management of cardiovascular patients in the community. Trends Cardiovasc Med 2019; 29:109-117.